- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–68
of 68
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- 4 mg CLS-TA Suprachoriodal Injection
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Uveitis
- Interventions
- Optical Coherence Tomography (OCT), Eye Exam
- Device · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
- Interventions
- RAY121
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more
- Conditions
- Autoimmune Connective Tissue Disorder, Immune System Diseases
- Interventions
- Anakinra
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
- Interventions
- Online Questionnaire
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
- Interventions
- H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
- Drug
- Lead sponsor
- Tampa Bay Uveitis Center, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Muckle Wells Syndrome, Autoinflammatory, Behcet's Disease
- Interventions
- XOMA 052
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anterior Uveitis
- Interventions
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Uveitis, Anterior, Panuveitis
- Interventions
- Placebo, LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Uveitis
- Interventions
- Brepocitinib PO QD, Placebo PO QD
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
- Interventions
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
- Interventions
- Adalimumab/Biosimilar
- Biological
- Lead sponsor
- Nisha Acharya
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- TRS01 eye drops
- Drug
- Lead sponsor
- Tarsier Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Palisades Park, New Jersey • San Antonio, Texas
- Conditions
- Behcet's Syndrome, Retinal Disease, Uveitis
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Ixekizumab Prefilled Syringe
- Drug
- Lead sponsor
- Massachusetts Eye Research and Surgery Institution
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Uveitis, JIA
- Interventions
- Adalimumab, Placebo
- Biological · Other
- Lead sponsor
- Nisha Acharya
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Behçet's Syndrome
- Interventions
- Apremilast, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland